Latest investigations into retatritide peptide reveal significant potential for addressing excess body and type 2 diabetes. The compound, a dual agonist of GLP-1 receptor and glucose-dependent insulinotropic polypeptide, looks to provide enhanced weight loss and glucose management compared existing medications. Ongoing patient studies are needed to